Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12000739 | 0.84 | TDP1 (0.49) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL6626231 | 0.83 | ALDH1A1 (0.46) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL28723015 | 0.82 | ALDH1A1 (0.45) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL357183 | 0.82 | SIRT6 (0.44) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL9084161 | 0.82 | PKM (0.44) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL23898722 | 0.82 | ABL1 (0.46) | MEN1KMT2ALMNAKDM4EALDH1A1 | |
| SCHEMBL2896179 | 0.81 | DTYMK (0.46) | TDP1MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL8064653 | 0.80 | PDGFRB (0.48) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL15996997 | 0.80 | PDGFRB (0.51) | TDP1SIRT6PDGFRBFGFR1PDGFRA | |
| SCHEMBL2900760 | 0.78 | MEN1 (0.43) | TDP1SIRT6PDGFRBFGFR1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. | 2015-06-25 | — | — | US | disclosed |
| EP-1814537-B1 | MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20130172344-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. | 2013-07-04 | — | — | US | disclosed |
| US-20130172344-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. | 2013-07-04 | — | — | US | disclosed |
| US-8232401-B2 | Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | JAPAN TOBACCO INC. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8232401-B2 | Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | JAPAN TOBACCO INC. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-7678783-B2 | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7531554-B2 | Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | JAPAN TOBACCO INC. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-7531554-B2 | Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | JAPAN TOBACCO INC. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20080269302-A1 | Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2008-10-30 | — | — | US | disclosed |
| CN-101133029-A | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK & CO INC (US) | 2008-02-27 | — | — | CN | disclosed |
| EP-1814537-A2 | MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7176220-B2 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | JAPAN TOBACCO INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176220-B2 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | JAPAN TOBACCO INC. (JP) | 2007-02-13 | — | — | US | disclosed |
| WO-2006055434-A2 | MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | TDP1 207/4885SIRT6 3069/4885PDGFRB 4682/4885 |
| US-20130172344-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR | IMPDH1, CDKL4, IMPDH2 | TDP1 183/4885SIRT6 2899/4885PDGFRB 4602/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | TDP1 204/4885SIRT6 2490/4885PDGFRB 4709/4885 |
| US-20080269302-A1 | Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN1 | TDP1 223/4885SIRT6 2284/4885PDGFRB 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.